|
Male sex
|
24 (57.1)
| |
|
Diagnosis
| | |
|
de novo AML
|
17 (40.5)
| |
|
ALL
|
12 (28.6)
| |
|
CML-AP
|
2 (4.8)
| |
|
MDS overt AML
|
10 (23.8)
| |
|
PCL
|
1 (2.4)
| |
|
Cytogenetics
| | |
|
Intermediate
|
17
| |
|
Poor
|
22
| |
|
ECOG PS
| | |
|
0
|
2 (4.8)
| |
|
1
|
25 (59.5)
| |
|
2
|
7 (16.7)
| |
|
3
|
8 (19.0)
| |
|
Status at allo-HCT
| | |
|
Primary refractory/Refractory relapse/Untreated MDS overt AML
|
7/32/3
| |
|
No. chemo regimens prior allo-HCT
| |
6 (0-18)
|
|
Time from diagnosis to allo-HCT (days)
| |
319 (23-3738)
|
|
Marrow blasts at allo-HCT
| |
26.0 (0.2-100)
|
|
Conditioning regimen
| | |
|
Intensified
|
9 (21.4)
| |
|
Standard
|
12 (28.6)
| |
|
Reduced-intensity
|
7 (16.7)
| |
|
Reduced-intensity + cytoreductive chemotherapy
|
14 (33.3)
| |
|
GVHD prophylaxis
| | |
|
None
|
3 (7.1)
| |
|
Calcineurin inhibitor alone
|
5 (11.9)
| |
|
Calcineurin inhibitor + sMTX
|
32 (76.2)
| |
|
Calcineurin inhibitor + MMF
|
2 (4.8)
| |
|
Donor (HLA-A, B and DRB1 antigens)
| | |
|
Matched related PB/BM
|
10/2
| |
|
Mismatched related PB/BM
|
3/1
| |
|
Matched unrelated BM
|
19
| |
|
Mismatched unrelated BM
|
1
| |
|
Umbilical cord blood
|
6
| |
